OSU as Network Lead Academic Participating Site for the NCI NCTN

OSU 作为 NCI NCTN 网络主导学术参与网站

基本信息

批准号：
9025473
负责人：
CLARA D BLOOMFIELD
金额：
$ 138.46万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-05-06 至 2019-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9025473
关键词：
Address Adult Affect Ally American College of Radiology Imaging Network Area Basic Science Biochemistry Biological Markers Biomedical Research Biometry CEBPA gene Cancer Center Cancer Hospital Cancer Patient Chronic Myeloid Leukemia Clinic Clinical Clinical Research Clinical Sciences Clinical Trials Clinical Trials Network Comprehensive Cancer Center Contracts Cytotoxic agent Data Decitabine Development Discipline Disease Eastern Cooperative Oncology Group Education Enrollment Epidemiologist Faculty Fostering Funding Gastrointestinal Stromal Tumors Gene Expression Profiling Generations Genetic Goals Grant Gynecologic Oncology Gynecologic Oncology Group Health Health Personnel Hematologic Neoplasms Hematopoietic Neoplasms Histology Imatinib Immunology Individual Inpatients Knowledge Laboratory Research Laboratory Scientists Lead Leadership Malignant Neoplasms Measures Medical Medical Oncology Minority Modeling Molecular Genetics National Clinical Trials Network National Surgical Adjuvant Breast and Bowel Project Nurses Oblimersen Ohio Operative Surgical Procedures Outcome Outpatients Pathologist Patient-Focused Outcomes Patients Peer Review Pentostatin Performance Pharmacists Pharmacodynamics Pharmacology Phase Physicians Postdoctoral Fellow Protocols documentation Psychiatrist Quality of life Radiation Radiation Oncologist Radiation Therapy Oncology Group Radio Rare Diseases Research Research Activity Research Design Research Infrastructure Research Personnel Resources Risk Science Scientist Site Solid Neoplasm Southwest Oncology Group Structure Surgical Oncologist Surgical Oncology Symptoms TNFRSF5 gene Testing Therapeutic Therapeutic Agents Therapeutic Index Tissues Toxic effect Training Translating Translational Research Translational trial Tumor Biology Universities base bcr-abl Fusion Proteins cancer prevention career development college design disorder subtype doctoral student improved improved outcome learning network lenalidomide leukemia meetings member new technology next generation next generation sequencing novel novel therapeutics phase 1 study phase 3 study pre-clinical preclinical study programs research study rituximab sound stem success targeted treatment treatment trial tumor heterogeneity

项目摘要

DESCRIPTION (provided by applicant): Faculty from The Ohio State University (OSU) are integrated into the scientific and administrative activities, participate in meetings, manage multiple core labs, design studies and enroll patients in all existing adult NCTN network groups using cancer center resources to leverage group resources. OSU investigators develop and lead studies designed to enroll patients on multi-disciplinary treatment trials as well as develop and perform correlative science related research studies, bringing special expertise in hematologic malignancies and solid tumors. Our medical, hematologic, surgical and radiation oncologists, trans planters, psychiatrists, pathologists, cytogeneticists, translational and basic laboratory scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research coordinators help to frame the clinical and basic science questions whose answers contribute to improved patient outcomes and to understanding tumor biology. The goal of this application is to provide the infrastructure to support OSU's participation in the scientific and clinical research activities of the NCI's NCTN Program as a Network Lead Academic Participating Site (NLAPS). We will use the support to make scientific discoveries about tumor biology, find better treatments and augment the quality of life for patients thus improving outcomes across the spectrum of cancers affecting adults. This comprehensive program aims to: 1) Investigate new therapeutic agents, and their toxicities in Phase I to 1 clinical trials; 2) Evaluate the efficacy nd toxicity of novel combinations based on preclinical data to exploit synergistic combinations more effectively; 3) Develop multi-modal approaches using surgical, immunological, and radio therapeutic measures in optimal combinations; 4) Integrate experts in molecular genetics, biochemistry, pharmacology, immunology, and biostatistics in the design and execution of therapeutic protocols; 5) Improve cancer outcomes through discovery and education of pre and post-doctoral students, nurses, allied medical personnel and physicians, 6) Understand and exploit tumor heterogeneity to fully exploit the value of targeted therapies, 7) Improve the management of cancer related symptoms, and 8) enroll patients on trials.

描述（由申请人提供）：俄亥俄州立大学（OSU）的教职员工都集成到科学和行政活动中，参加会议，管理多个核心实验室，设计研究并使用癌症中心的所有现有成人NCTN网络组中，使用癌症中心资源来利用组资源。 OSU研究人员正在开发和铅研究，旨在让患者接受多学科治疗试验，并开发和执行相关的与科学相关的研究研究，从而在血液学恶性肿瘤和实体瘤方面具有特殊的专业知识。我们的医学，血液学，外科和放射肿瘤学家，跨性别者，精神科医生，病理学家，细胞遗传学家，转化和基本实验室科学家，统计学家，流行病学家，护士，药剂师，药剂师以及临床研究协调员有助于构建对临床和基础科学问题的理解，从而对临床和基础科学的回答有助于改善tamor tamor tamor tamory的答案。该应用程序的目的是提供基础架构，以支持OSU参与NCI的NCTN计划作为网络领先学术参与网站（NLAP）的科学和临床研究活动。我们将使用支持来对肿瘤生物学进行科学发现，找到更好的治疗方法，并提高患者的生活质量，从而改善影响成年人的癌症范围的结果。该综合计划的目的是：1）研究新的治疗剂及其在I期中的毒性至1个临床试验； 2）根据临床前数据评估新型组合的功效ND毒性，以更有效地利用协同组合； 3）使用最佳组合中的手术，免疫和无线电治疗方法开发多模式方法； 4）在治疗方案的设计和执行中整合了分子遗传学，生物化学，药理学，免疫学和生物统计学的专家； 5）通过发现和教育博士后和博士后学生，护士，盟军医疗人员和医生，改善癌症结果，6）理解和利用肿瘤异质性，以充分利用靶向疗法的价值，7）提高与癌症相关症状的管理，以及8）招募患者。